CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin Apr 15, 2020 8:00am EDT
CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals Apr 13, 2020 8:00am EDT
CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets Mar 23, 2020 8:00am EDT
CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results Mar 12, 2020 4:05pm EDT
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 Mar 05, 2020 4:05pm EST
CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free Mar 03, 2020 8:00am EST
CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors Feb 11, 2020 8:00am EST
CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance Jan 28, 2020 8:00am EST
